Measuring Health-Related Quality Of Life (HRQoL) In Leukemia Patients

Published Dec 17, 2012
Chicago, IL, USA – Researchers at Northwestern University have developed a new questionnaire to measure the quality of life (QoL) issues associated with leukemia: The Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu). This questionnaire joins a large family of similar questionnaires targeted to various malignancies and other chronic conditions, the Functional Assessment of Chronic Illness Therapy (see www.facit.org). The FACT-Leu is a brief, valid measure of general and leukemia-specific symptoms and concerns associated with leukemia and its treatment. Prior to the development of the FACT-Leu, options for measuring leukemia-specific QoL in clinical trials or practice were limited.  Working with an international team of investigators and patients to ensure cross-cultural applicability of the questionnaire, lead author David Cella, Ph.D., and his team developed and validated the FACT-Leu to measure the QoL of patients with acute and chronic leukemia. According to Cella, “Understanding the impact of leukemia and its treatments has never been more important, with an emerging array of treatment options and schedules that patients must consider and endure. By considering patient concerns such as the severity of symptoms and/or treatment effects, family burden, life disruption and disability, clinicians and researchers are better able to understand the broader implications of the disease and its impact on patients and their families.” The study, "Measuring Health-Related Quality of Life in Leukemia: The Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu) Questionnaire," is published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

International Study Confirms Universally Applicable Framework for Defining Digital Health Interventions

Jan 21, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a comprehensive international study demonstrating that the PICOTS-ComTeC framework serves as an effective universal standard for defining patient-facing digital health interventions. The report, “Towards a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report” was published in the January 2026 issue of Value in Health.

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×